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Introduction
A central nervous system relapse is a serious complication
of aggressive lymphomas. Prognosis is generally regarded
as poor and standard therapies of relapsed central
nervous system lymphoma (CNSL) have not yet been es-
tablished [1]. In contrast, therapeutic results have been
much better in primary CNS lymphomas (PCNSL) with a
regimen developed by our group, consisting of combined
systemic and intraventricular chemotherapy with deferred
radiotherapy and applied within a pilot/phase II study in
65 patients [2]. The overall response rate was 71% for
the whole group, median time to treatment failure (TTF)
was 21 months, and median overall survival 50 months.
Results were significantly better in patients <60 years of
age with a 86% overall response rate and a 75% survival
fraction at five years.
CNS relapse is common in acute lymphatic leukemia (ALL)
and Burkitt lymphoma (30–50%), less common (2–10%)
in diffuse large B cell lymphoma (DLBCL). In indolent
lymphoma CNS relapse is 0–4%, inmantle cell lymphoma
4–23% [3], [4].
In DLBCL CNS relapse occurs in median 5–12 months
from original diagnosis. Leptomenigeal (33–100%) occur-
rence is more frequent than parenchymal (10–56%). In
half of the cases of CNS relapse there is an additional
systemic relapse. Median survival is only 2–6 months
[3], [4], [5], [6], [7], [8], [9]. High-dose chemotherapy with
stem cell transplantation leads to a median event free
survival (EFS) of 0.4 to 1.5 years and an overall survival
(OS) of 0.8 to 2.2 years [10]. A pilot study with MTX/Ifo
has been recently performed [4].
Since data on secondary central nervous system lymph-
oma (SCNSL) is limited, an efficient therapy has not been
established yet [1]. Therefore, we have retrospectively
evaluated the clinical characteristics and outcome of
SCNSL patients at our centers.
Patients and methods
Eligibility criteria, initial treatment and
patient characteristics
All patients with SCNSL treated at Bonn University Hospit-
al and Cologne University Hospital from 04/2003–
12/2007 were included into the analysis. 23 patients
could be identified.
60% of patients had a DLBCL, 30% a follicular lymphoma,
10% presented with other histologic subtypes.
Patients with SCNSL had received 6–8 cycles of CHOP
(Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Pred-
nisone) or CHOP-like combination chemotherapy as initial
treatment. At cerebral relapse, 4/23 patients received
an acute leukemia regimen (GMALL-B-ALL protocol), 3/23
patients received whole brain irradiation to a total of
40 Gy in 2 Gy fractions alone, one was treated with a
chemotherapy according to the BEAM protocol and
autologous bone marrow transplantation and 15/23 pa-
tients received a combined systemic and intraventricular
polychemotherapy according to the Bonn protocol
(Table 1). Systemic high-dose MTX was administered as
a 24 h infusion under vigorous hydration, urine alkaliza-
tion and preconditions as well as dose modifications as
described in [2]. Ifosfamide, cyclophosphamide, ARA-C,
vinca-alkaloids and dexamethasone (cycles 3 to 6) were
administered as described in [2]. In patients developing
a peripheral neuropathy under treatment, application of
vinca-alkaloids was omitted in subsequent cycles. Dexa-
methasone, if given postoperatively, was tapered and
omitted during the first cycle.
18/23 patients (78%) were male with 13 /23 patients
(57%) being older than 60 years. The median age at dia-
gnosis was 60 years (range 41–77).
Evaluation of response and toxicity
Response criteria were used in line with recommenda-
tions of the International Primary Central Nervous System
Lymphoma Collaborative Group (IPCG) consensus (for
primary CNS lymphomas), and therefore all respective
magnetic resonance imaging (MRI) studies were re-eval-
uated for this analysis according to these criteria [11]:
Complete response (CR) was defined as disappearance
of all enhancing lesions on MRI of the brain in patients
being off steroids, unconfirmed complete response (CRu)
was defined as a minimal residual enhancing lesion in
the region of biopsy/hemorrhage without change or with
involution during follow up, partial response (PR) as re-
duction of enhancing tumor volume by more than 50%,
progressive disease (PD) as increase of tumor volume of
more than 25% or occurrence of new lesions and stable
disease (SD) as any other situation [12]. Treatment failure
was defined as PD or SD, relapse after initial response,
death or discontinuation of chemotherapy due to any
cause. Acute toxicity was graded according to the WHO
system [13].
Statistics
Students T-test was used to analyse for statistical signi-
ficance. A p-value <0.05 was considered significant. For
probability of survival calculations, the Kaplan-Meier
2/7GMS German Medical Science 2011, Vol. 9, ISSN 1612-3174
Patrij et al.: Isolated central nervous system relapse of systemic ...
Table 1: Modified Bonn Chemotherapy Protocol for Primary CNS Lymphoma
Sequence of cycles: A1 (d. 1–5), B1 (d. 22–26), C1 (d. 43–49); A2 (d. 64–68), B2 (d. 85–89), C2 (d. 106–112). Cycles A to C
(A1 to C1) are repeated once (A2 to C2).
method was used and was presented graphically by SPSS
(SPSS Inc., Chicago, Illinois, U.S.A. Version 11.5.1).
Results
The response rates of the pooled cohort of patients with
SCNSL were as follows: CR in 12 cases, PR in 3 cases,
and PD in 8 cases (overall response: 65%). Interestingly,
response rates were higher with the Bonn protocol as
compared to the ALL protocol (Table 2).
Median overall survival was 7 months (Figure 1). The
predictive value of age on the overall survival time was
analysed. Among the patients who suffered from SCNSL,
median OS averaged 7 months for patients <60 years
(n=10) and 12 months for the group =60 years (n=13),
respectively (Figure 2).
After a median follow-up of 6.5 months (range 1–68),
15/23 (65%) patients with SCNSL relapsed a second
time (n=5) or progressed (n=10). The respective five pa-
tients with recurrence all showed a relapsed within the
CNS. Median time to relapse was 20 months. Eleven
cases were submitted to salvage therapy at time of
second relapse or PD, whereas 4 patients with a PD did
not receive another therapy because of an “early death”
or a decline in general condition. For 4/5 patients, treat-
ment at relapse consisted of radiotherapy and 1/5 pa-
tients received a polychemotherapy according to the Bonn
protocol for PCNSL. Response to relapse treatment was
in one case CR, in one case PR, and in 3 cases PD
(Table 2, Table 3). Treatment at second PDwas radiother-
apy alone (n=4), radiotherapy in combination with temo-
zolomide (n=1), and BEAM chemotherapy (n=1). Re-
sponse to treatment was in one case PR and in 5 cases
PD (Table 3). Patients without specific treatment (n=4)
suffered from PD, as expected.
Prognosis of relapsed/progressive SCNSL was dismal.
Median OS was short with only 7 months survival time
after relapse. 15/23 patients (65%) with a relapse or a
PD died within the observation period due to complica-
tions of CNS relapse (Figure 3).
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Table 2: Outcome in patients with recurrent or refractory SCNSL
Figure 1: Overall survival of patients with SCNSL
Figure 2: Overall survival of patients with SCNSL according to age of patients
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Table 3: Response rates in patients with recurrent or refractory SCNSL
Figure 3: Survival function according to the outcome after initial treatment
Discussion
CNS relapse in patients with aggressive lymphoma is
uncommon. The cumulative incidence is only 2.8% and
2.2%, respectively [14], [15]. However, the prognosis of
patients with CNS relapse is dismal.
In contrast to clinical trials in PCNSL, the rarity of second-
ary central nervous system lymphoma is one of the
reasons why prospective trials on this entity are difficult
to perform. Therefore, there is only limited data on treat-
ment strategies for SCNSL. At present there is a clinical
trial running in Germany.
However, since in our centers results with a combined
systemic and intraventricular MTX-based chemotherapy
has resulted in very promising results in PCNSL [2], we
favored this regimen in the majority of patients with
SCNSL that came to our institutions.
Our series includes 23 patients diagnosed and treated
for SCNSL between 2003 and 2007. 15/23 patients
(65%) received the same therapy at cerebral relapse as
patients with PCNSL (data not shown), which consisted
of high-dose methotrexate (MTX) in combination with
vincristine, ifosfamide, prednisolone and cytarabine (Bonn
protocol). Yet, compared to other studies on SCNSL that
reported median survival times from 1–5 months [14],
[15], [16] and response rates under 50%, our series
confirms the view of different authors, that early introduc-
tion of HD-methotrexate is important when treating sec-
ondary CNS lymphoma as well as PCNSL and is associ-
ated with longer survival [1], [16].
The age of the patients at the time of diagnosis was pre-
dictive for the survival time among the patients with
PCNSL. Patients younger than 60 years old had a signifi-
cantly longer survival time than patients who were more
than 60 years old (37 months/13 months) (p<0.001). In
contrast to PCNSL, a statistically significant association
between the age of the patients and long-term survival
for the SCNSL-collective could not be verified. This is most
likely due to the comparatively small group of only 23
evaluated patients with SCNSL in our series. However,
most reported studies, with a collective of over 100 pa-
tients, recognized age as a predictor for longer survival
times [1], [17]. Therefore, treatment strategies for SCNSL
must be adjusted to the patient’s age, in a similar fashion
to the previously modified treatments for PCNSL.
A median follow-up of 6.5 months (range 1–68) showed
that 15 patients with a SCNSL (65%) relapsed after initial
response or progressed within the CNS. Treatment at re-
lapse/progression was heterogeneous dependent of the
regimens applied at first relapse and due to the lack of
approved and established treatment strategies for such
clinical courses. 56% of the patients with second cerebral
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relapse achieved CR or PR after salvage therapy, while
the response rate of patients with a refractory disease
was only 14%, respectively. Relapse or PD of the lymph-
oma dims the high overall response rates after initial
treatment for SCNSL in both groups and leads to the re-
spectively poor prognosis. Therefore, new treatment
strategies for PCNSL and SCNSL are needed to prevent
the risk of relapse and refractory disease.
In conclusion, HD-MTX chemotherapy according to the
Bonn Protocol is effective in SCNSL patients although the
prognosis of patients with SCNSL seems to be worse as
compared to PCNSL patients. Prognosis of relapsed and
refractory CNSL patients is dismal. Median overall survival
was only 7.1 months in patients with SCNSL. Therefore,
new treatment strategies are urgently needed.
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